Published in Nat Med on October 23, 2011
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov (2014) 2.98
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature (2014) 2.85
Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res (2013) 2.74
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature (2015) 1.91
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell (2014) 1.70
The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res (2012) 1.63
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med (2016) 1.62
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol (2015) 1.51
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol (2016) 1.49
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One (2015) 1.48
Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res (2015) 1.43
Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res (2012) 1.43
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell (2016) 1.36
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell (2014) 1.28
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res (2013) 1.23
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res (2012) 1.20
ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol (2014) 1.19
Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med (2012) 1.18
Transcription factor Oct1 is a somatic and cancer stem cell determinant. PLoS Genet (2012) 1.15
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res (2013) 1.15
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2013) 1.12
New cast for a new era: preclinical cancer drug development revisited. J Clin Invest (2013) 1.11
Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci U S A (2013) 1.11
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res (2013) 1.09
Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget (2015) 1.06
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget (2014) 1.06
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res (2014) 1.06
Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS One (2013) 1.05
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res (2014) 1.05
Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol (2013) 1.04
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Front Bioeng Biotechnol (2016) 1.04
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov (2014) 1.02
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther (2013) 1.02
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res (2013) 1.02
Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One (2015) 1.02
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res (2013) 1.01
Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel) (2013) 1.01
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol (2013) 0.99
A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res (2014) 0.97
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell (2016) 0.96
A phenotypic mouse model of basaloid breast tumors. PLoS One (2012) 0.95
Next-generation sequence analysis of cancer xenograft models. PLoS One (2013) 0.94
Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol (2015) 0.94
Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biol Med (2016) 0.91
Lobular breast cancer: molecular basis, mouse and cellular models. Breast Cancer Res (2015) 0.91
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Clin Cancer Res (2016) 0.91
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res (2014) 0.91
Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. Nat Protoc (2014) 0.90
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly. Curr Oncol Rep (2014) 0.89
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling. Mol Cancer (2015) 0.88
Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol (2016) 0.88
Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Sci Rep (2015) 0.87
Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology. PLoS One (2013) 0.87
The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep (2014) 0.87
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res (2014) 0.86
Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med (2013) 0.86
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget (2015) 0.86
Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res (2016) 0.86
Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A (2015) 0.85
Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. PLoS One (2014) 0.85
Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol (2012) 0.85
Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells. Breast Cancer Res (2013) 0.85
MicroRNA Regulation of Human Breast Cancer Stem Cells. J Clin Med (2015) 0.84
Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep (2016) 0.83
Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers (Basel) (2012) 0.83
First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One (2014) 0.83
The in ovo CAM-assay as a xenograft model for sarcoma. J Vis Exp (2013) 0.83
Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech (2015) 0.83
Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell (2014) 0.83
The promise and challenge of ovarian cancer models. Transl Cancer Res (2015) 0.82
Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol (2014) 0.82
Genomic profiling of patient-derived colon cancer xenograft models. Medicine (Baltimore) (2014) 0.82
MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. Sci Adv (2015) 0.82
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep (2015) 0.82
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol Cells (2016) 0.82
Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One (2013) 0.81
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene (2015) 0.81
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials (2015) 0.81
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med (2013) 0.81
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget (2016) 0.81
Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem (2014) 0.80
Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget (2016) 0.80
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer (2008) 2.45
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia (1996) 1.66
Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46
Anticancer drug development: the grand challenges. Nat Rev Drug Discov (2010) 1.42
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol (2008) 1.20
Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.19
Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res (2003) 1.10
Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. Clin Breast Cancer (2010) 1.01
The role of preclinical animal models in breast cancer drug development. Breast Cancer Res (2009) 0.91
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA (2002) 3.63
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Ewing's sarcoma family of tumors: current management. Oncologist (2006) 2.97
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Statistical modeling for selecting housekeeper genes. Genome Biol (2004) 2.73
Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia: a randomized trial. Arch Surg (2010) 2.58
miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech (2008) 2.34
Successful implementation of the Department of Veterans Affairs' National Surgical Quality Improvement Program in the private sector: the Patient Safety in Surgery study. Ann Surg (2008) 2.34
Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. Nat Genet (2012) 2.25
Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell (2008) 2.24
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res (2010) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Maternal smoking during pregnancy, prematurity and recurrent wheezing in early childhood. Pediatr Pulmonol (2012) 2.09
Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr (2006) 2.08
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem (2007) 2.01
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
Esthetic periodontal surgery for impacted dilacerated maxillary central incisors. Am J Orthod Dentofacial Orthop (2012) 1.97
Variation in Institutional Review processes for a multisite observational study. Am J Surg (2005) 1.93
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One (2012) 1.72
MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A (2005) 1.70
Multivariable predictors of postoperative respiratory failure after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg (2007) 1.68
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer (2008) 1.66
Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg (2007) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Next generation tools for genomic data generation, distribution, and visualization. BMC Bioinformatics (2010) 1.56
Synthesis and preliminary biological studies of 3-substituted indoles accessed by a palladium-catalyzed enantioselective alkene difunctionalization reaction. J Am Chem Soc (2010) 1.56
Surgical site infection prevention: the importance of operative duration and blood transfusion--results of the first American College of Surgeons-National Surgical Quality Improvement Program Best Practices Initiative. J Am Coll Surg (2008) 1.56
Barriers to advancement in academic surgery: views of senior residents and early career faculty. Am J Surg (2013) 1.56
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Abnormal thyroid function predicts mortality in patients receiving long-term peritoneal dialysis: a case-controlled longitudinal study. J Chin Med Assoc (2012) 1.49
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol (2010) 1.47
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 1.43
Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. Clin Rheumatol (2011) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Management of biliary tract disease during pregnancy. J Am Coll Surg (2010) 1.39
Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. BMJ Open (2012) 1.38
Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol Cell Biol (2002) 1.38
Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res (2009) 1.37
Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. J Thorac Cardiovasc Surg (2003) 1.37
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Hoxc10 and Hoxd10 regulate mouse columnar, divisional and motor pool identity of lumbar motoneurons. Development (2008) 1.34
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
Visual analog scales for assessing surgical pain. J Am Coll Surg (2005) 1.32
Annotation and expression profile analysis of 2073 full-length cDNAs from stress-induced maize (Zea mays L.) seedlings. Plant J (2006) 1.31
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res (2011) 1.30
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
Genome-wide transcriptome analysis of two maize inbred lines under drought stress. Plant Mol Biol (2009) 1.26
IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol (2012) 1.25
Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues. Mod Pathol (2007) 1.25
Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci (2011) 1.24
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat (2008) 1.22